CIK 0000949858
- Non-accelerated filer
- Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Tickers
- ACHV QUIT
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 954343413
- Phone
- +1 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
Securities
- ACHV Common stock Nasdaq
- QUIT Common Shares Nasdaq
- 4 Exercise or conversion Director acquired 21,130 shares (option exercise)
- 4 Exercise or conversion President and CEO acquired 871 shares (option exercise)
- 4 Open-market sale 10% owner sold 100,000 shares at $20.79 ($2,078,610)
- 4 Open-market sale 10% owner sold 88,400 shares at $21.41 ($1,892,290)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion President and CEO acquired 24,809 shares (option exercise)
- 4 Open-market sale 10% owner sold 450,000 shares at $5.95 ($2,677,500)
- 4/A Open-market buy CFO and Secretary bought 10,000 shares at an average $6.77 ($67,700)
- 4/A Open-market buy CFO and Secretary bought 3,000 shares at an average $2.43 ($7,278)
Page 19 of 24 · 465 filings